Novavax COVID-19 Vaccine Receives Final Approvals
On July 20, the Kansas Department of Health & Environmental endorsed federal regulatory approvals of the COVID-19 vaccine manufactured by Novavax.
The Novavax vaccine becomes the fourth COVID-19 vaccine option available in the U.S. It is authorized for use as a primary series of two doses in adults ages 18 and older.
The vaccine contains harmless protein subunits of the COVID-19 virus, alongside another ingredient called an adjuvant, that help the immune system respond to the virus in the future. Vaccines using protein subunits have been used for more than 30 years in the U.S., beginning with the first licensed hepatitis B vaccine, and today including vaccines for influenza, whooping cough and shingles.
The vaccine is expected to be available through pharmacies and healthcare providers beginning in early August.